IL237228B - Stem cells that improve healing - Google Patents

Stem cells that improve healing

Info

Publication number
IL237228B
IL237228B IL237228A IL23722815A IL237228B IL 237228 B IL237228 B IL 237228B IL 237228 A IL237228 A IL 237228A IL 23722815 A IL23722815 A IL 23722815A IL 237228 B IL237228 B IL 237228B
Authority
IL
Israel
Prior art keywords
stem cell
cell enhancing
therapeutics
enhancing therapeutics
stem
Prior art date
Application number
IL237228A
Other languages
English (en)
Hebrew (he)
Other versions
IL237228A0 (en
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/060684 external-priority patent/WO2013059373A2/fr
Priority claimed from PCT/US2013/025981 external-priority patent/WO2013123084A1/fr
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of IL237228A0 publication Critical patent/IL237228A0/en
Publication of IL237228B publication Critical patent/IL237228B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL237228A 2012-08-14 2015-02-15 Stem cells that improve healing IL237228B (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261683155P 2012-08-14 2012-08-14
US201261684654P 2012-08-17 2012-08-17
US201261693712P 2012-08-27 2012-08-27
PCT/US2012/060684 WO2013059373A2 (fr) 2011-10-17 2012-10-17 Milieu pour la prolifération et l'induction de cellules souches
PCT/US2013/025981 WO2013123084A1 (fr) 2012-02-13 2013-02-13 Procédé de détection de cellules fœtales en circulation
US201361837560P 2013-06-20 2013-06-20
PCT/US2013/055015 WO2014028668A2 (fr) 2012-08-14 2013-08-14 Composés thérapeutiques activant les cellules souches

Publications (2)

Publication Number Publication Date
IL237228A0 IL237228A0 (en) 2015-04-30
IL237228B true IL237228B (en) 2021-03-25

Family

ID=50101604

Family Applications (1)

Application Number Title Priority Date Filing Date
IL237228A IL237228B (en) 2012-08-14 2015-02-15 Stem cells that improve healing

Country Status (8)

Country Link
US (2) US9932407B2 (fr)
EP (1) EP2885000A4 (fr)
JP (4) JP6664219B2 (fr)
CN (3) CN111388664A (fr)
AU (2) AU2013302620B2 (fr)
CA (1) CA2882222A1 (fr)
IL (1) IL237228B (fr)
WO (1) WO2014028668A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239182B (zh) * 2008-10-06 2014-07-09 米纳瓦生物技术公司 Muc1*抗体
AU2015243948B2 (en) * 2014-04-07 2020-10-15 Minerva Biotechnologies Corporation Anti-NME antibody
AU2016219350A1 (en) * 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
WO2017177199A2 (fr) * 2016-04-08 2017-10-12 Iti Health, Inc. Anticorps se fixant à la plectine-1 et leurs utilisations
US20210107989A1 (en) * 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
JP7379347B2 (ja) 2017-10-11 2023-11-14 ジィールバイオ，インコーポレーテッド プレクチン１結合抗体およびその使用
CA3126391A1 (fr) * 2019-01-11 2020-07-16 Minerva Biotechnologies Corporation Anticorps muc1* antivariables et leurs utilisations
EP3920693A4 (fr) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation Anticorps anti-nme et méthode de traitement du cancer ou de métastases cancéreuses
WO2021252551A2 (fr) 2020-06-08 2021-12-16 Minerva Biotechnologies Corporation Anticorps anti-nme et procédé de traitement du cancer ou de métastases cancéreuses
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2069439A1 (fr) * 1989-12-15 1991-06-16 Susumu Iwasa Anticorps monoclonaux, leur production et leur utilisation
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
JP2005508839A (ja) * 2001-03-29 2005-04-07 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペプチドおよびｍｕｃ１タンパク質に対する抗体
EP2116248A1 (fr) * 2001-09-05 2009-11-11 Minerva Biotechnologies Corporation Compositions et procédés pour le traitement du cancer
US20030235868A1 (en) * 2002-04-22 2003-12-25 Dyax Corporation Antibodies specific for mucin polypeptide
US7202346B2 (en) * 2002-07-03 2007-04-10 Immunogen Inc. Antibodies to non-shed Muc1 and Muc16, and uses thereof
EP2527365A3 (fr) * 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Prolifération des cellules exprimant MUC1
US7825092B2 (en) * 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
WO2008070171A2 (fr) * 2006-12-06 2008-06-12 Minerva Biotechnologies Corp. Procédé d'identification et de manipulation de cellules
WO2008101231A2 (fr) * 2007-02-16 2008-08-21 Endocyte, Inc. Procédés et compositions de traitement et de diagnostic d'une maladie rénale
CN102239182B (zh) * 2008-10-06 2014-07-09 米纳瓦生物技术公司 Muc1*抗体
WO2010042891A2 (fr) * 2008-10-09 2010-04-15 Minerva Biotechnologies Corporation Procédé permettant d'induire une pluripotence dans des cellules
CN102264765B (zh) * 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
WO2010138171A2 (fr) * 2009-05-23 2010-12-02 Incube Labs, Llc Méthodes de traitement du cancer faisant appel à des cellules souches
WO2010144887A1 (fr) * 2009-06-11 2010-12-16 Minerva Biotechnologies Corporation Procédés de culture de cellules souches et progénitrices
KR101853418B1 (ko) * 2010-06-16 2018-05-02 미네르바 바이오테크놀로지 코포레이션 암 세포의 역분화

Also Published As

Publication number Publication date
WO2014028668A2 (fr) 2014-02-20
US9932407B2 (en) 2018-04-03
IL237228A0 (en) 2015-04-30
CN111388664A (zh) 2020-07-10
JP2018070640A (ja) 2018-05-10
CA2882222A1 (fr) 2014-02-20
EP2885000A2 (fr) 2015-06-24
WO2014028668A3 (fr) 2014-05-01
JP6664219B2 (ja) 2020-03-13
AU2018220126B2 (en) 2020-07-23
AU2013302620A1 (en) 2015-04-02
CN108175856A (zh) 2018-06-19
AU2018220126A1 (en) 2018-09-13
AU2013302620B2 (en) 2018-08-02
US20150299334A1 (en) 2015-10-22
EP2885000A4 (fr) 2015-12-23
JP6757712B2 (ja) 2020-09-23
CN108175856B (zh) 2024-01-26
JP2015526446A (ja) 2015-09-10
CN104717980A (zh) 2015-06-17
JP2022025136A (ja) 2022-02-09
JP2020109101A (ja) 2020-07-16
US20170121406A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
IL277912A (en) Intentional healing
HK1202051A1 (en) Erythrocyte-binding therapeutics
HK1211623A1 (en) Cell lines
HK1209762A1 (en) Targeted therapeutics
HK1201556A1 (en) Enhanced stem cell composition
SG11201500329WA (en) Stem cell microparticles
SG11201406336YA (en) Stem cell microparticles
IL237228A0 (en) Stem cells that improve healing
SG11201503579RA (en) Cell culture med
PL2758523T3 (pl) Zrębowe komórki macierzyste
GB201411223D0 (en) None
EP2698839A4 (fr) Bloc de cellules
EP2911230A4 (fr) Cellule
HK1213649A1 (zh) 計時器
EP2831949A4 (fr) Cellules à sodium-oxygène
GB201303603D0 (en) Improvements relating to valves
EP2863459A4 (fr) Cellule plate
GB2501710B (en) Improvements in valves
EP2937605A4 (fr) Structure de soupape
GB201218496D0 (en) Cell
GB201212848D0 (en) Stem cell product
GB201205972D0 (en) Stem cell product
GB201410091D0 (en) None
GB201119658D0 (en) Cell
GB201214618D0 (en) Double ended cell

Legal Events

Date Code Title Description
FF Patent granted